share_log

微創醫療：海外監管公告

MICROPORT: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Feb 23 08:55
Summary by Moomoo AI
微創醫疗科學有限公司（微創醫疗）公布其持股約40.32%的上海微創心脈醫療科技（心脈醫療科技）於上海證券交易所科創板發布的2023年度業績快報。該快報顯示，心脈醫療科技在2023年實現營業總收入約11.87億元，同比增長32.43%；營業利潤約5.74億元，增長38.21%；利潤總額約5.72億元，增長38.26%；歸屬於母公司所有者的淨利潤約4.92億元，增長37.98%。此外，基本每股收益為6.81元，同比增長37.30%，加權平均淨資產收益率增加4.21個百分點至26.43%。報告期末，公司總資產增長112.62%，归属于母公司所有者的每股净资产增長94.56%。業績增長主要得益於公共衛生問題的逐步消除、業務規模擴大、產品銷量增長以及海外市場銷售收入的顯著提升。公司強調，上述財務數據為初步核算數據，未經會計師事務所審計，最終數據將以公司2023年年度報告為準。
微創醫疗科學有限公司（微創醫疗）公布其持股約40.32%的上海微創心脈醫療科技（心脈醫療科技）於上海證券交易所科創板發布的2023年度業績快報。該快報顯示，心脈醫療科技在2023年實現營業總收入約11.87億元，同比增長32.43%；營業利潤約5.74億元，增長38.21%；利潤總額約5.72億元，增長38.26%；歸屬於母公司所有者的淨利潤約4.92億元，增長37.98%。此外，基本每股收益為6.81元，同比增長37.30%，加權平均淨資產收益率增加4.21個百分點至26.43%。報告期末，公司總資產增長112.62%，归属于母公司所有者的每股净资产增長94.56%。業績增長主要得益於公共衛生問題的逐步消除、業務規模擴大、產品銷量增長以及海外市場銷售收入的顯著提升。公司強調，上述財務數據為初步核算數據，未經會計師事務所審計，最終數據將以公司2023年年度報告為準。
MICROCHUN MEDICAL SCIENCE CO., LTD. (MICROCHUN MEDICAL) ANNOUNCED ITS 2023 ANNUAL RESULTS ANNOUNCEMENT PUBLISHED ON THE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE (MICRO CHUNG MEDICAL TECHNOLOGY) OF APPROXIMATELY 40.32%. Cardiac Medical Technologies achieved total operating revenue of approximately $11.87 billion in 2023, up 32.43% year-on-year; operating profit of approximately $5.74 billion, up 38.21%; total profit of approximately $5.72 billion, up 38.26%; net profit attributable to parent company owners was approximately $4.92 billion, up 37.98%, according to the Express. In addition, basic earnings per share were $6.81, an increase of 37.30% year-on-year, and the weighted average net asset yield increased 4.21 percentage points to 26.43%. At the end of the reporting period, the Company's total assets grew by 112.62%, reflecting a 94.56% increase in net...Show More
MICROCHUN MEDICAL SCIENCE CO., LTD. (MICROCHUN MEDICAL) ANNOUNCED ITS 2023 ANNUAL RESULTS ANNOUNCEMENT PUBLISHED ON THE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE (MICRO CHUNG MEDICAL TECHNOLOGY) OF APPROXIMATELY 40.32%. Cardiac Medical Technologies achieved total operating revenue of approximately $11.87 billion in 2023, up 32.43% year-on-year; operating profit of approximately $5.74 billion, up 38.21%; total profit of approximately $5.72 billion, up 38.26%; net profit attributable to parent company owners was approximately $4.92 billion, up 37.98%, according to the Express. In addition, basic earnings per share were $6.81, an increase of 37.30% year-on-year, and the weighted average net asset yield increased 4.21 percentage points to 26.43%. At the end of the reporting period, the Company's total assets grew by 112.62%, reflecting a 94.56% increase in net assets per share attributable to the owners of the parent company. The growth in results was mainly driven by the gradual elimination of public health issues, business expansion, increased product sales and a significant increase in overseas sales revenue. THE COMPANY EMPHASIZES THAT THE ABOVE FINANCIAL DATA ARE PRELIMINARY AUDIT DATA AND THE FINAL DATA WILL BE BASED ON THE COMPANY'S 2023 REPORT WITHOUT AUDITING BY THE ACCOUNTING FIRM.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more